Ubs Group Ag Chinook Therapeutics, Inc. Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$18.66 - $38.58 $93,822 - $193,980	5,028 Added 6.53%	82,016 $3.15 Million
Q1 2023 May 12, 2023	BUY	$21.53 - $26.8 $177,062 - $220,403	8,224 Added 11.96%	76,988 $1.78 Million
Q4 2022 Feb 08, 2023	BUY	$18.63 - $27.35 $844,237 - $1.24 Million	45,316 Added 193.26%	68,764 $1.8 Million
Q3 2022 Nov 10, 2022	BUY	$17.51 - $23.37 $163,228 - $217,855	9,322 Added 65.99%	23,448 $461,000
Q2 2022 Aug 10, 2022	SELL	$12.59 - $18.8 $759,025 - $1.13 Million	-60,288 Reduced 81.02%	14,126 $248,000
Q1 2022 May 16, 2022	BUY	$12.02 - $16.69 $353,243 - $490,485	29,388 Added 65.27%	74,414 $1.22 Million
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $213,201 - $335,657	19,944 Added 79.52%	45,026 $735,000
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $275,517 - $356,015	23,958 Added 2131.49%	25,082 $320,000
Q2 2021 Aug 13, 2021	BUY	$13.6 - $18.98 $15,286 - $21,333	1,124 New	1,124 $16,000
Q1 2021 May 12, 2021	SELL	$14.17 - $19.11 $5,384 - $7,261	-380 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$11.9 - $20.91 $4,522 - $7,945	380 New	380 $6,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.